
decision-making with the most dynamic view of cancer.1
- >1 million unique patient profiles
- >350,000 epigenomic profiles
- 150+ tumor types
- EMR data integration and data partnerships providing comprehensive clinical context
Compared with normal cells, cancer cells exhibit a distinct methylation pattern. InfinityAI maps the unique epigenomic fingerprint of cancer by examining differences in these methylation patterns to help detect cancer recurrence sooner and provide insights to improve therapy selection.
The InfinityAI-powered capabilities of Guardant360® Liquid CDx, Guardant360® Tissue, and Guardant Reveal® tests deliver complete, actionable multiomic insights to guide more informed decisions.†
Help inform available treatment options.
Helps identify patients who may benefit from ICI monotherapy.3
Helps identify ESR1-WT patients who may have favorable outcomes with fulvestrant over chemotherapy.4
Enhanced detection of MTAP to help inform clinical trial enrollment.5
Uses an epigenomic signature to predict which patients have a PD-L1 score of <50%.
Assesses confidence that the cancer is negative for biomarkers with associated FDA-approved therapies.6
Identifies the presence of HPV or EBV, now with high-risk HPV genotyping.7,8
Enhanced detection of ALK fusions can help inform use of ALK inhibitor therapy.9
Helps optimize treatment and reduce toxicity by identifying alleles in CYP2D6, DPYD, UGT1A1, HLA-B, and TPMT.10,11
Helps inform clinical trial enrollment and therapy decisions for select indications.12,13
Determines HRD status to help inform use of PARP inhibitors and platinum-based chemotherapies.14
On Guardant360 Liquid CDx, reported as a professional service.
Discover more insights about your patient's tumor.
Uses epigenomic signatures to help identify tissue of origin.15,16
Assesses proportion of adenocarcinoma, squamous cell carcinoma, and small cell lung carcinoma subtypes to supplement histologic assessment.17
Assesses confidence for the presence of HR, HER2, and TNBC subtypes to supplement histologic assessment.18
Measures ctDNA to accurately quantify disease burden.19
On Guardant360 Liquid CDx, reported as a professional service.
Guardant offers a portfolio of revolutionary liquid and tissue tests—powered by InfinityAI—all with the convenience of a single testing partner.
The #1 liquid biopsy†20
The most advanced multiomic tissue test‡
Monitor cancer across the care continuum
View our portfolio of tests, powered by InfinityAI.
See the evidence backing Guardant tests.AI, artificial intelligence; ctDNA, circulating tumor DNA; EBV, Epstein-Barr virus; HLA, human leukocyte antigen; HRD, homologous recombination deficiency; HPV, human papillomavirus; ICI, immune checkpoint inhibitor; ML, machine learning; PARP, poly-ADP ribose polymerase; SERD, selective estrogen receptor degrader.
- *The only real-world database to include NGS epigenomic results for >400,000 patients.
- †Statement applies to Guardant360 Liquid LDT as reported in a professional service report, which is part of Guardant360 Liquid CDx. The professional service report is not reviewed nor approved by the FDA. #1 liquid biopsy statement is based on stated brand utilization from a market research survey.
- ‡Compared to other leading comprehensive tissue tests. The “most advanced” referring to the first and only commercially available tissue test to deliver multiomic insights from a single input.
- §When compared to other tissue-free testing companies. Comparisons are based on publicly available information as of April 2026.
Important note: Guardant Reveal®, Guardant360® Liquid CDx, and Guardant360® Tissue were developed as Laboratory Developed Tests (LDTs), and their performance characteristics determined by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. These tests have not been cleared or approved by the US FDA.
InfinityAI is not a standalone customer product. “Powered by InfinityAI” refers to Guardant Health artificial intelligence and machine learning technology used in development of product features. These features are reported as professional service and have not been cleared or approved by the US FDA.
References: 1. Guardant Health data on file. October 19, 2023. Guardant Health, Inc. Redwood City, CA. 2. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31-46. doi:10.1158/2159-8290.CD-21-1059 3. Gordon S, Wang J, Zhang S, et al. Blood-based integration of epigenomic profiles, TMB, and MSI to predict immune checkpoint inhibitor response in advanced non-small cell lung cancer (aNSCLC). Cancer Res. 2026;86(suppl 7):Abstract 100. doi:10.1158/1538-7445.AM2026-100 4. Zhang S, Zhang N, Ramani V, et al. DNA methylation-based classifier predicts SERD benefit in ESR1 wild-type HR+/HER2- breast cancer. Cancer Res. 2026;86(suppl 7):2279. doi:10.1158/1538-7445.AM2026-2279 5. Yalamanchili G, Gordon S, Warner E, et al. Multi-omic method to detect MTAP homozygous deletions enables high sensitivity detection from blood samples. Cancer Res. 2026;86(suppl 7):1012. doi:10.1158/1538-7445.AM2026-1012 6. Gross AM, Wang H, Freschi B, et al. An expanded negative prediction algorithm for actionable mutations utilizing genomic and epigenomic profiling in cfDNA. Cancer Res. 2026;86(suppl 7):107. doi:10.1158/1538-7445.AM2026-107 7. Huang Y, Wang J, Yang W, et al. Precision therapeutic targets for HPV-positive cancers: an overview and new insights. Infect Agents Cancer. 2025;20(1):17. doi:10.1186/s13027-025-00641-7 8. Xu JY, Wei XL, Ren C, et al. Association of plasma Epstein-Barr virus DNA with outcomes for patients with recurrent or metastatic nasopharyngeal carcinoma receiving anti–programmed cell death 1 immunotherapy. JAMA Netw Open. 2022;5(3):e220587. doi:10.1001/jamanetworkopen.2022.058 9. Sun J, Yang L, Liu D, et al. Diagnostic accuracy of circulating tumor DNA for detection of ALK rearrangement in lung cancer: a systematic review and meta-analysis of 14 studies. PLoS One. 2025;20(8):e0330855. doi:10.1371/journal.pone.0330855 10. US Food and Drug Administration. Safety labeling update for capecitabine and fluorouracil (5-FU) on risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency. Accessed March 30, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/safety-labeling-update-capecitabine-and-fluorouracil-5-fu-risks-associated-dihydropyrimidine 11. Nogueiras-Álvarez R, Pérez Francisco I. Pharmacogenetics in oncology: a useful tool for individualizing drug therapy. Br J Clin Pharmacol. 2024;90(10):2483-2508. doi:10.1111/bcp.1618 12. Gormally MV, Chen MF, Noronha AM, et al. Next-generation sequencing for HLA genotype screening and matching to HLA-restricted therapies. JAMA Oncol. 2025;11(1):74-76. doi:10.1001/jamaoncol.2024.5364 13. Seth R, Messersmith H, Funchain P, et al. Systemic therapy for melanoma: ASCO guideline rapid recommendation update. J Clin Oncol. 2022;40(21):2375-2377. doi:10.1200/JCO.22.0094 14. Safabakhsh P, Tolkunov D, Overstreet B, et al. HRD status prediction in patients with advanced breast, prostate, ovarian and pancreatic cancers in a liquid biopsy assay. J Clin Oncol. 2025;43(suppl 16):3074. doi:10.1200/JCO.2025.43.16_suppl.3074 15. Forouzmand E, He Y, Gittelman R, et al. A novel methylation-based classifier to identify cancer signal of origin using blood based testing. Abstract 6365. Cancer Res. 2025;85(8 suppl 1):6365. doi:10.1158/1538-7445.AM2025-6365 16. Forouzmand E, He Y, Greenwald WY, et al. Epigenomic-based classifier for cancer signal of origin in liquid biopsy for cancer of unknown primary. J Clin Oncol. 2025;43(suppl 16):3073. doi:10.1200/JCO.2025.43.16_suppl.3073 17. Valouev A, Tian W, Singh K, et al. Non-invasive cell free DNA (cfDNA) methylation profiling for accurate proportional quantification of lung cancer subtypes. Abstract 1142. Cancer Res. 2025;85(8 suppl 1):1142. doi:10.1158/1538-7445.AM2025-1142 18. Tolkunov D, Weipert C, Wienke S, et al. Liquid based methylation profiling for quantification of breast cancer subtypes. Abstract 3247. Cancer Res. 2025:85(8 suppl 1):3247. doi:10.1158/1538-7445.AM2025-3247 19. Gross A, Zhao J, Quinn K, et al. Landscape of epigenomic tumor fraction in a large pan-cancer cfDNA cohort. Abstract 5936. Cancer Res. 2025;85(8 suppl 2):5936. doi:10.1158/1538-7445.AM2025-5936 20. Guardant Health data on file. Late-stage chart audit. April 2026.


